SUPPRELIN LA Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Supprelin La, and when can generic versions of Supprelin La launch?
Supprelin La is a drug marketed by Endo Pharm and is included in one NDA. There is one patent protecting this drug.
This drug has three patent family members in three countries.
The generic ingredient in SUPPRELIN LA is histrelin acetate. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the histrelin acetate profile page.
DrugPatentWatch® Generic Entry Outlook for Supprelin La
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be June 16, 2026. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for SUPPRELIN LA
International Patents: | 3 |
US Patents: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 3 |
Clinical Trials: | 2 |
Patent Applications: | 1,073 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for SUPPRELIN LA |
DailyMed Link: | SUPPRELIN LA at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for SUPPRELIN LA
Generic Entry Date for SUPPRELIN LA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
IMPLANT;SUBCUTANEOUS |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for SUPPRELIN LA
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
National Cancer Institute (NCI) | Phase 3 |
Southwest Oncology Group | Phase 3 |
University of Colorado, Denver | Phase 2 |
Pharmacology for SUPPRELIN LA
Drug Class | Gonadotropin Releasing Hormone Receptor Agonist |
Mechanism of Action | Gonadotropin Releasing Hormone Receptor Agonists |
Anatomical Therapeutic Chemical (ATC) Classes for SUPPRELIN LA
US Patents and Regulatory Information for SUPPRELIN LA
SUPPRELIN LA is protected by one US patents.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of SUPPRELIN LA is ⤷ Try a Trial.
This potential generic entry date is based on patent ⤷ Try a Trial.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting SUPPRELIN LA
Compositions and methods for treating precocious puberty
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: METHOD OF TREATMENT OF CHILDREN WITH CENTRAL PRECOCIOUS PUBERTY
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Endo Pharm | SUPPRELIN LA | histrelin acetate | IMPLANT;SUBCUTANEOUS | 022058-001 | May 3, 2007 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for SUPPRELIN LA
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Endo Pharm | SUPPRELIN LA | histrelin acetate | IMPLANT;SUBCUTANEOUS | 022058-001 | May 3, 2007 | ⤷ Try a Trial | ⤷ Try a Trial |
Endo Pharm | SUPPRELIN LA | histrelin acetate | IMPLANT;SUBCUTANEOUS | 022058-001 | May 3, 2007 | ⤷ Try a Trial | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for SUPPRELIN LA
When does loss-of-exclusivity occur for SUPPRELIN LA?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Canada
Patent: 70960
Estimated Expiration: ⤷ Try a Trial
European Patent Office
Patent: 73293
Estimated Expiration: ⤷ Try a Trial
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering SUPPRELIN LA around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Denmark | 0551698 | ⤷ Try a Trial | |
World Intellectual Property Organization (WIPO) | 2006009801 | ⤷ Try a Trial | |
Austria | 149345 | ⤷ Try a Trial | |
Canada | 2570960 | COMPOSITIONS ET METHODES DE TRAITEMENT DE LA PUBERTE CENTRALE PRECOCE (COMPOSITIONS AND METHODS FOR TREATING CENTRAL PRECOCIOUS PUBERTY) | ⤷ Try a Trial |
European Patent Office | 0551698 | Fabrication d'articles hydrophiles hydro-gonflables et dispositifs de délivrance de médicaments (Manufacture of water - swellable hydrophilic articles and drug delivery devices) | ⤷ Try a Trial |
Germany | 69217900 | ⤷ Try a Trial | |
Denmark | 0551698 | ⤷ Try a Trial | |
>Country | >Patent Number | >Title | >Estimated Expiration |